Mpox outbreak: epidemiological overview, 7 November 2024
Updated 12 December 2024
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-overview/mpox-outbreak-epidemiological-overview-7-november-2024
This report contains the latest information on Clade IIb mpox cases in the UK, which have been regularly reported since May 2022. This report does not contain information relating to the Clade I mpox outbreak which is predominantly occurring overseas, please see latest update on cases of Clade Ib mpox.
This epidemiological overview provides an update to the number of confirmed and highly probable Clade IIb mpox cases in England, Northern Ireland, Scotland and Wales since the outbreak was recognised in May 2022. Clade Ib cases are not included in these figures.
Mpox is a zoonotic infection, caused by the virus called MPXV that occurs mostly in West and Central Africa. Prior to 2022, cases diagnosed in the UK had been either imported from countries where mpox is endemic or in contacts with documented epidemiological links to imported cases. Between 2018 and 2021, there had been 7 cases of mpox in the UK. Of these, 4 were imported, 2 were cases in household contacts, and one was a case in a health care worker involved in the care of an imported case. There was no documented community transmission in previous outbreaks.
Current epidemiological situation of Clade IIb mpox up to 31 October 2024
Detection of cases of Clade IIb mpox infection, acquired within the UK, were confirmed in England from 6 May 2022. The outbreak has mainly been in gay, bisexual, and other men who have sex with men without documented history of travel to endemic countries.
Suspected mpox samples that are positive using a mpox polymerase chain reaction (PCR) test are classified as confirmed cases. Samples which are positive using an orthopox PCR test are classified as highly probable cases. Orthopox is the group of viruses which includes mpox. The counts below combine both of these categories. Clade typing is conducted on confirmed mpox cases at UKHSA’s Rare and Imported Pathogens Laboratory.
Up to 31 December 2022, there were 3,732 confirmed and highly probable Clade IIb mpox cases reported in the UK. Of these, 3,553 were in England, 34 were in Northern Ireland, 97 were in Scotland and 48 were in Wales.
In 2023 and 2024 (up to 31 October 2024), there have been a total of 378 cases of Clade IIb mpox reported in the UK. Of these, 356 were in England (161 cases were presumed to have acquired mpox in the UK, 118 were acquired outside the UK and 77 are awaiting classification), 13 were in Scotland (8 were imported cases acquired outside the UK, 4 were presumed to have acquired mpox in the UK and one is awaiting classification), 2 were in Wales (both imported case acquired outside the UK), and 7 were in Northern Ireland (3 were presumed to have acquired mpox in the UK, one was an imported case acquired outside the UK and 3 are awaiting classification).
Figure 1 shows the monthly number of cases in England in 2023 and 2024, where there were between one and 41 cases per month, compared to the monthly high of 1,339 cases in July 2022.
Figure 1. Number of confirmed and highly probable Clade IIb mpox cases in England, by month in 2023 and 2024
Table 1. Number of confirmed and highly probable Clade IIb mpox cases by UK nation of residence, 6 May 2022 to 31 October [note 1]
| UK nation | Cases reported in 2022 [note 2] | Cases presumed acquired in the UK in 2023 and 2024 | Cases presumed acquired outside the UK (imported) in 2023 and 2024 | Cases awaiting classification in 2023 and 2024 | Total (2022 to 2024) |
|---|---|---|---|---|---|
| England | 3,553 | 161 | 118 | 77 | 3,909 |
| Northern Ireland | 34 | 3 | 1 | 3 | 41 |
| Scotland | 97 | 4 | 8 | 1 | 110 |
| Wales | 48 | 0 | 2 | 0 | 50 |
| Total | 3,732 | 168 | 129 | 81 | 4,110 |
Note 1: Based on data extracted on 4 November 2024.
Note 2: Figures for 2022 start from 6 May 2022 and combine UK acquired and imported cases.
Data sources
Mpox surveillance data in England is based on mpox and orthopox virus test results from the Rare and Imported Pathogens Laboratory (RIPL), which is the UK Health Security Agency (UKHSA) mpox reference laboratory, and other UK laboratories with mpox and orthopox testing.
Counts of confirmed cases in Wales, Northern Ireland, and Scotland are submitted to UKHSA by Public Health Wales, Public Health Agency Northern Ireland, and Public Health Scotland respectively.
Information about this publication
These figures are used for official reporting of mpox confirmed case counts in the UK.
England counts may differ from those published in the Notifications of infectious diseases (NOIDs) causative agents weekly report. This is due to differences in timings of when the data is compiled, and differences in processing of duplicate data (for example, if a person has tested more than once but insufficient information is provided to identify them).
As mpox continues to be a notifiable infection, please refer to UKHSA’s NOIDs reports for weekly updates (but not cumulative totals) on laboratory-notified mpox cases in England.
While data cleaning is carried out routinely, corrections can be applied between reports, such as updates to patient information and the removal of quality assurance samples from laboratory surveillance systems.
Additional resources
Mpox outbreak: technical briefings
Mpox contact tracing guidance: classification of contacts and advice for vaccination and follow-up